How to drive down the cost of monoclonal antibody manufacturing

Russell Miller, VP, global sales and marketing, Enzene shares how to drive down the cost of monoclonal antibody manufacturing.

Monoclonal antibodies (mAbs) have become central to modern biopharmaceutical therapy, with clinical applications spanning oncology, autoimmune diseases, and infectious disorders. Yet despite their clinical significance, mAbs remain expensive to manufacture, posing a persistent barrier to affordability and access, particularly in resource-limited settings. 

With biotech companies still struggling to secure funding and capital markets remaining tight, there…